Testosterone Undeconate (Nebido, BAY86-5037) + Placebo

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Hypogonadism

Conditions

Hypogonadism

Trial Timeline

Sep 1, 2010 → Jul 1, 2011

About Testosterone Undeconate (Nebido, BAY86-5037) + Placebo

Testosterone Undeconate (Nebido, BAY86-5037) + Placebo is a approved stage product being developed by Bayer for Hypogonadism. The current trial status is terminated. This product is registered under clinical trial identifier NCT01092858. Target conditions include Hypogonadism.

What happened to similar drugs?

5 of 18 similar drugs in Hypogonadism were approved

Approved (5) Terminated (2) Active (12)
Topical Testosterone SolutionEli LillyApproved
AndroGel® + PlaceboAbbVieApproved
AndroGel 1.62%AbbVieApproved
NEBIDO + PLACEBOBayerApproved
JatenzoICON plc.Approved
🔄Testosterone MD-LotionEli LillyPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01092858ApprovedTerminated